Series A · Biotech · Copenhagen, Denmark · Founded 2023 · 6–10 employees
Sidera Bio is a clinical-stage biotechnology company developing first-in-class triple agonist therapeutics that simultaneously activate GLP-1, GIP, and FGF21 receptor pathways for cardiometabolic diseases. The company has secured exclusive global rights outside Greater China to develop MWN105, a novel triple agonist for obesity and metabolic diseases. In December 2025, Sidera raised $109 million in one of Denmark's largest Series A biotech rounds, led by Novo Holdings, Forbion, RA Capital, and Gilde Healthcare. The company is positioned to enter first-in-human clinical studies in Europe in 2026.
No open roles listed right now.